NRLPA:OHLT

Cancer victims urge court to end J&J bankruptcy roadblock to lawsuits

Register now for FREE unlimited access to Reuters.comRegisterSept 19 (Reuters) – People suing Johnson & Johnson over the company’s talc products urged an appeals court on Monday to revive their claims, saying the profitable company should not be allowed to use a bankrupt subsidiary to block lawsuits alleging the products cause cancer.They asked a panel …

Cancer victims urge court to end J&J bankruptcy roadblock to lawsuits Read More »

3M combat earplug lawsuits to proceed, judge rules, despite bankruptcy case

The logo of Down Jones Industrial Average stock market index listed company 3M is shown in Irvine, California April 13, 2016. REUTERS/Mike Blake Register now for FREE unlimited access to Reuters.comRegisterAug 26 (Reuters) – 3M Co must face more than 230,000 lawsuits accusing it of selling defective earplugs to the U.S. military, after a U.S. …

3M combat earplug lawsuits to proceed, judge rules, despite bankruptcy case Read More »

Bluebird’s $2.8 million gene therapy becomes most expensive drug after U.S. approval

Signage is seen outside of the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, U.S., August 29, 2020. REUTERS/Andrew Kelly/File PhotoRegister now for FREE unlimited access to Reuters.comRegisterAug 17 (Reuters) – The U.S. Food and Drug Administration on Wednesday approved bluebird bio’s (BLUE.O) gene therapy for patients with a rare disorder requiring regular …

Bluebird’s $2.8 million gene therapy becomes most expensive drug after U.S. approval Read More »

Newly-launched U.S. drugs head toward record-high prices in 2022

Median annual price for new U.S. drugs this year is $257,000Eight of 13 drugs launched in 2022 priced over $200,000 per yearSome drugmakers disclose less information on pricingAug 15 (Reuters) – Drugmakers are launching new medicines at record-high prices this year, a Reuters analysis has found, highlighting their pricing power even as Congress moves to …

Newly-launched U.S. drugs head toward record-high prices in 2022 Read More »

Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln deal

Aug 8 (Reuters) – Pfizer Inc on Monday agreed to pay $5.4 billion in cash for sickle cell disease drugmaker Global Blood Therapeutics (GBT.O), as it looks to capitalize on a surge in revenue from its COVID-19 vaccine and treatment.Pfizer will pay $68.50 per GBT share, which represents a 7.3% premium to its Friday closing …

Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 bln deal Read More »

Large U.S. law firms mostly quiet on abortion ruling, are walking a ‘tightrope’

June 26 (Reuters) – The largest U.S. law firms did not take a public stance following the U.S. Supreme Court’s reversal of Roe v. Wade on Friday, diverging from the approach of some major companies that have made statements on the closely watched abortion case.The high court’s 6-3 Dobbs decision upheld a Republican-backed Mississippi law …

Large U.S. law firms mostly quiet on abortion ruling, are walking a ‘tightrope’ Read More »